Patient monitoring should include signs and symptoms of MI, stroke, and liver injury, as described above in the warnings and precautions section.

A treat-to-target management strategy includes urate-lowering therapy (febuxostat/allopurinol) dosing directed by serial serum urate measurements to accomplish a target serum urate is recommended over a fixed-dose drug strategy. Consequently, monitor serum urate levels and adjust the dose of febuxostat to maintain the serum urate target of <6 mg/dl. (ACR 2020 guidelines).

A lower serum urate target (<5 mg/dL) helps promote the rapid dissolution of crystals. It is suggested for patients with severe gout until total crystal dissolution and resolution of gout, according to EULAR (European Alliance of Associations for Rheumatology) guidelines.